Twist Bioscience (TWST) Q4 FY2026 Earnings Call: Guidance and Outlook
The company provided formal revenue and margin guidance for fiscal 2027, projecting continued growth across their primary business segments. They also outlined a multi-year capital investment plan to support scaling operations.
About Twist Bioscience. Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips.
Dombey's summary of the Twist Bioscience Q4 FY2026 earnings call held Nov 12, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.